Companies / Nuvectis Pharma, Inc.

Nuvectis Pharma, Inc.

Nasdaq: NVCTCIK 1875558FORT LEE, NJ

Financials

Revenue—
Net income$-26.44M
Total debt—
Cash$22.16M
Diluted EPS$-1.32
Shares outstanding32.6M

Ownership

32.6M shares outstanding · as of Jul 31, 2026
22.9%Insiders
Ownership
Insiders22.94%7,475,429
Institutions14.11%4,598,842
Public float62.94%20,507,262

% of common shares outstanding (exact, from the latest cover-page filing). Institutions are quarterly 13F snapshots; insiders reflect current officers & directors.

Insiders 4

View all →
Insider% of sharesShares
Bentsur RonCEOChairman & CEO · Director · 10% owner
11.28%3,675,924
Poradosu EnriqueChief Science & Business Off
5.54%1,806,319
Shemesh ShayChief Dev. & Ops. Officer
5.50%1,793,068
Carson Michael J.Vice President, Finance
0.61%200,118

Institutional holders 49

View all →
HolderValue% of shares
BlackRock, Inc.$18.41M3.07%
Vanguard Group Inc$6.38M2.60%
Iridian Asset Management LLC/CT$5.04M2.00%
State Street Corporation$4.56M0.76%
Geode Capital Management, LLC$2.97M1.18%
Baldwin Wealth Partners LLC/MA$2.93M1.16%
Occam Crest Management LP$2.87M1.17%
Susquehanna International Group, LLP$1.01M0.41%
Northern Trust Corp$878.9K0.36%
Oppenheimer & Co Inc$555.4K0.23%

Activity

View all →
InsidersInstitutions
What insiders are doing in this stock (Form 4).
DateActorActionSecurityValueShares ΔPosition afterImpact
Jan 6, 2026Shemesh Shay
Executive
GrantCommon Stock$0+150K
+9.13%
1,793,068
5.50% of shares
low
Jan 6, 2026Poradosu Enrique
Executive
GrantCommon Stock$0+150K
+9.06%
1,806,319
5.54% of shares
low
Jan 6, 2026Carson Michael J.
Executive
GrantCommon Stock$0+61K
+44.05%
200,118
0.61% of shares
low
Jan 6, 2026Bentsur Ron
CEO
GrantCommon Stock$0+150K
+4.25%
3,675,924
11.28% of shares
low

Securities

via CUSIP / OpenFIGI
SymbolTypeMarketCUSIPFIGI
NVCTCommon StockEquity67080T108BBG012BCR149